CoChat

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Purpose Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic drugs for small cell lung cancer (SCLC). The present systematic review had as its objective the evaluation of their role, as components of chemotherapy regimens, on survival.Methods Published randomised clinical trials (from 1980 to 1998) were selected comparing, in SCLC patients, chemotherapy regimens, given as first-line therapy. One arm (the experimental arm) had to include CDDP and/or VP16, while another had to omit the same drug(s). Trials quality was assessed by two published scores (Chalmers and European Lung Cancer Working Party (ELCWP)). For each individual trial, the hazard ratio (HR) of the survival distributions was estimated on the basis of reported statistics or, if not available, by extracting, from the survival graphical representations, the data required to construct the difference between expected and observed numbers of events as calculated in the log-rank statistic. A combined hazard ratio was obtained by the Peto method (a value < 1 meaning a benefit for CDDP and/or VP16).Results Thirty-six trials eligible for our systematic review were identified, classified into four groups (I-IV): group I, 1 trial testing a CDDP-based regimen (without VP16) against another arm not including either CDDP or VP16; group II, 17 trials testing a VP16-based regimen (without CDDP) against a regimen without VP16 and CDDP; group III, nine trials comparing a regimen including CDDP and VP16 with a regimen using neither drug; and, finally, group IV, nine trials comparing a regimen based on both drugs with a regimen based on VP16 only. Overall, Chalmers and ELCWP scores correlated well (r(S) = 0.76, P < 0. 001) and had respective median scores of 50.3 and 63.7%. The number of eligible patients did not have a significant impact on the scores as well as the trials group, the trial positivity (a positive trial defined as showing itself a statistically significant survival benefit for the experimental regimen), overall or in categories, and the year of publication. Combined hazard ratios with 95% confidence intervals were: 0.70 (0.41-1.21) for group I, 0.72 (0.67-0.78) for II, 0.57 (0.51-0.64) for III, and 0.74 (0.66-0.83) for IV, showing a survival benefit in favour of regimens including etoposide alone or in combination with cisplatin, justifying with high significance levels the use of each of these drugs. Overall survival benefits could also be shown for regimens including CDDP (HR = 0.61; confidence interval (CI), 0.57-0.66), as well as for those including VP16 (HR = 0. 65; CI, 0.61-0.69). Robustness of these results has to be confirmed with appropriate randomised trials.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0169-5002(00)00127-6

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 56 references

Research works printed but not linked: 1

  1. Luce, 1998, Revue critique des études randomisées évaluant le rôle de la radiothérapie adjuvante à la chimiothérapie dans le traitement du cancer bronchique à petites cellules au stade limité, Rev. Mal. Resp., 15, 633

Cited by

See all 270

Metadata

Authors
Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P.
Affiliations
  • Institut Jules Bordet (BE)
  • Centre Hospitalier Universitaire de Lille (FR)
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2000-10
Volume
30
Issue
1
Pages
23-36
ISSN
0169-5002 (ISSN-L)
OpenAlex
W2108113897
Cited by
270
References
55
Citations by year
2026: 4 · 2025: 13 · 2024: 17 · 2023: 12 · 2022: 8 · 2021: 11 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 9 · 2016: 7 · 2015: 8 · 2014: 9 · 2013: 19 · 2012: 13
FWCI
1.10
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Lung Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • ORBi UMONS (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
small cell lung cancer, etoposide, cisplatin, first-line chemotherapy, survival, hazard ratio, trial quality assessment, combination chemotherapy, randomized controlled trials, meta-analysis of trials
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Cisplatin, Etoposide, Humans, Lung Neoplasms, Prognosis, Survival Analysis, Randomized Controlled Trials as Topic, Carcinoma, Small Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. https://app.cochat.ai/papers/10.1016/s0169-5002(00)00127-6
The paper
Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P. (2000). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. https://doi.org/10.1016/s0169-5002(00)00127-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.